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ABSTRACT
Diabetes is one of the major life-threatening health problems worldwide today. It is one of the most fast-
growing diseases that cause many health complications and a leading cause of decreasing life expectancy 
and high mortality rate. Many studies have suggested several different types of intervention to treat Type 
1 diabetes such as insulin therapy, islet transplantation, islet xenotransplantation and stem cell therapy. 
However, issues regarding the efficacy, cost and safety of these treatments are not always well addressed. 
For decades, diabetes treatments with few side effects and long-lasting insulin independence has remained 
one of the most challenging tasks facing scientists. Among the treatments mentioned above, application 
of human islet transplantation in patients with type 1 diabetes has progressed rapidly with significant 
achievement. Again, the lack of appropriate donors for islet transplantation and its high cost have led 
researchers to look for other alternatives. In this review, we discuss very pertinent issues that are related 
to diabetes treatments, their availability, advantages, disadvantages and also cost.   
Keywords: Cell therapy, diabetes economy, 
diabetes treatments, insulin, islet transplantation, 
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INTRODUCTION
Diabetes mellitus is a life-threatening disease 
that might be complicated by cardiovascular 
and kidney diseases, ketoacidosis and skin 
conditions (Habener, 2004; Nathan et al., 
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2009). Diabetes mellitus is a fast-growing metabolic disease (Kaul et al., 2013; IDF, 2015). In 
2015, the International Diabetes Federation estimated that worldwide, more than 415 million 
people live with diabetes and 5% of that population are diagnosed with type 1 diabetes (IDF, 
2015; ADA, 2017). The incidence of diabetes is dramatically increasing and predicted to 
more than double by the year 2040 (IDF, 2015). Patients with diabetes are costly to maintain 
and in 2015, it was shown to be an economic burden on the health maintenance schemes of 
undeveloped and developed countries, amounting to USD673 billion per annum, which is 
equivalent to 12% of total health expenditure (Guariguata, 2012). In Malaysia, prevalence of 
diabetes is growing and is expected to rise to 21.6% of the adult population by 2020. Statistics 
show that patients with type 1 diabetics are 0.6% of the whole population with diabetes in 
Malaysia (IDF 2015). 
Diabetes is a chronic disease caused when the pancreas either does not produce sufficient 
insulin or the body fails to use insulin (IDF, 2017). Insulin facilitates cellular uptake of glucose 
and regulates carbohydrates and fat metabolism. In type 1 diabetes, insulin secreting cells are 
destroyed by autoimmune attack (Table 1). Although insulin injections or treatment using 
synthetic medication may temporarily control diabetes, these drugs cannot cure the disease.
Table 1 
Autoantibodies against pancreatic antigens in type 1 diabetes  
Auto-Ab Abbreviation Antigen Expression Explanation
Anti-insulin Abs IAA Pancreas Detected in 50% type 1 diabetic 
children
Anti-glutamate 
decarboxilase Abs
GADA Pancreas and nervous 
system
Found in 70%-80% newly 
diagnosed diabetics
Anti-insulinoma 
associated 2 Abs
IA2-A Pancreas Found in about 60% of type 1 
diabetics
Anti-islet cell Abs ICA Pancreas Detected in about 70%-80% newly 
diagnosed type 1 diabeticd
Abs against the zinc 
channel ZnT8
SCL338A Pancreas -
(Akerblom et al., 2002; American Association for Clinical Chemistry, 2016). 
Recently, cell therapy was deemed to hold great potential for developing a permanent cure for 
diabetes. One of the most recent successes in cell therapy is islet transplantation in the bile 
duct of the liver in type 1 diabetics (Malka et al., 2000; Margener & Baillie, 1997). However, 
the main problem with this treatment method is the lack of compatible human islet sources for 
transplantation. Stem cells such as embryo and adult stem cells that can potentially differentiate 
into insulin secreting islet-like clusters and xenogeneic islet have shown some promising results 
for treatment of diabetes (Habener, 2004). However, the success of cell therapy in treating 
diabetes is limited by the lack of human pancreatic β-cells to produce insulin. Alternatively, 
it was suggested that other animal species could be used as sources of pancreatic β-cells. It 
was demonstrated in diabetic mice that some β-cells, for example, embryo blastocysts and 
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pancreas, liver, bone marrow and islet cells, from various mammalian species have the potential 
to reverse symptoms of diabetes (Wedemeyer et al., 2016). 
Insulin and Cell Therapies for Diabetes
In the early 1920s, the extract of bovine pancreas cells injected in a diabetic patient reduced 
diabetic signs such as glycosuria and hyperglycemia. In 1921, insulin was discovered by 
Frederick G. Banting (Karamitsos, 2011). Since the advent of genetic engineering, many useful 
immunoproteins and hormones, including biosynthetic human insulin (Sara et al., 1998), can be 
prepared by recombinant DNA techniques and produced in various efficient expression systems 
including bacteria, yeast and mammalian cells (Razis et al., 2006; Abdul Razis et al., 2008, Tam 
et al., 2012). Direct treatment with naked DNA containing the gene of interest, the insulin gene, 
into the host tissue or selected organs is possible but this method faces a lot of uncertainty in 
terms of potential integration in the host genome that may lead to unwanted cell transformation. 
Until now, biosynthetic insulin and its analogues serve as the mainstay in diabetic treatment. 
Insulin therapy reduces diabetic signs; however, diabetics require frequent monitoring of blood 
glucose while experiencing various side effects, including hypoglycemia (Cryer et al., 2009), 
unusual ocular disturbance (Lee & Traboulsi, 2008), lipohyperthrophy (Blanco et al., 2013), 
hypersensitivity (Wong et al., 2007), anaphylaxis (Ghazavi & Johnston, 2011), hypertension 
(Arima et al., 2002), weight gain (Russell-Johnes & Khan, 2007), myocardial infarction 
(Malmberg et al., 2005), renal dysfunction (Patrick et al., 1992), hemolytic anemia (Dhaliwal 
et al., 2004) and gastrointestinal distress (Drugs, 2017).
Edmonton Protocol
In 1972, Lacy et al. (1972) showed that transplantation of islet allografts in the portal vein 
of pancreactomised patients reduced insulin independence for long periods. In 2000, the 
Edmonton Protocol was introduced by a University of Alberta research group (Shapiro et 
al., 2000; McCall & Shapiro, 2012). The Edmonton Protocol is a method of implantation of 
pancreatic islets for treatment of type 1 diabetes mellitus. This protocol reduced the risk of 
islet graft rejection and inhibitors such as inadequate islet cluster, insufficient prophylaxis, 
diabetogenic consumption and drugs that prevented attainment of insulin independence 
(Shapiro et al., 2000). According to the protocol, in order to gain sufficient islet quantity and 
complete insulin independence, islets of two to four donors are required to be harvested and 
transplanted into recipients. The optimum islet number for transplantation in type 1 diabetics 
is approximately 11,000 IEQ/kg body weight. In this protocol, the period of cold ischemia and 
the need for exposure to xenoprotein such as fetal calf serum, were minimised and the islets 
could be transplanted immediately after harvest without need of prior long-term freezing or 
in-vitro maintenance (Gaglia, Shapiro, & Weir, 2005). The Edmonton Protocol success rate is 
80% with insulin independence during the first year, although in the long term the results are 
quite varied (Ryan et al., 2002; Shapiro et al., 2006).
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Stem Cell Therapy 
Stem cells are unspecialised cells of multicellular organs with potential for differentiation into 
other cell types during the embryonic period or in adults. Pluripotent and multipotent stem cells 
can differentiate to other types of cell tissue to repair dysfunctional cells or maintain tissue or 
organ sustainability (Habener, 2004; Fuchs et al., 2004; Wagers & Weissman, 2004; Young et 
al., 2004). Stem cells have three main properties, which are, multipotency as in adult tissues, 
pluripotency as in the blastocyst of embryos and totipotency as in a fertilised egg. The most 
distinguishable characteristic of stem cells is their capacity for self-renewal, transmutability to 
other cell types, extreme motility and immune resistance in the host (Habener, 2004; Abraham 
et al., 2004; Yang, 2004).  
Islet progenitor cells (IPC) are found not only in the islets but also in the ducts and 
acinar tissue of the pancreas (Tang et al., 2004; Pessina et al., 2004). The bone marrow, liver, 
umbilical cord blood cells and embryo stem cells are the origin of IPC. The IPC differentiate 
into an islet-like cluster (ILC) and is shown in vitro to have huge potential of proliferation 
and insulin secretion upon exposure to growth factors such as fetal serum, epidermal growth 
factor (EGF), nerve growth factor (NGF) and fibroblast growth factor (FGF). Treatment 
with proliferation and differentiation inhibitors provides the ILC with the ability to express 
and secrete insulin, glucagon, somatostatin, glucagon-like peptide-1 (GLP-1) and pancreatic 
polypeptide (PP) (Lechner & Habener, 2003). In addition, primary epithelial cells harvested 
from the skin, umbilical cord and intestine also have the capacity to differentiate into islets 
when maintained in the appropriate environment and culture medium. However, the insulin 
production and functionality of these epithelial cells are lower than that of native pancreatic 
islets (Lechner & Habener, 2003).  
Islet precursor cells in the adult pancreas has been suggested to impact pancreas 
development during embryonic damage, such as those caused by surgery and drugs (Dor et al., 
2004). Pancreatic β-cells can still maintain insulin secretion even in cases of insult to pancreatic 
tissues (Dor et al., 2004). Multipotent stem cells can regenerate new cells from damaged islets 
and can most probably differentiate into functional β-cells (Dor et al., 2004).
Islet Transplantation 
Islet transplantation has been suggested to be the ultimate treatment for the recovery of glucose 
homeostasis in patients with type 1 or late type 2 diabetes (Figure 1). Functional transplanted 
islets alleviate hypoglycemia and reestablish glucose homeostasis through the restoration of 
insulin production. Type 1diabetes can be cured by pancreas replacement. This was shown in 
pancreactomised diabetic dogs transplanted with fragments of the pancreas beneath the skin. 
The grafts kept the dogs alive even though they were not in physical contact with the digestive 
organs. This procedure was used in human experimentation with the grafting of sheep pancreas 
in a patient with type 1 diabetes. Unfortunately, although the graft improved the glycosuria, 
the patient did not survive after falling into adiabetic coma (Gaglia et al., 2005). 
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The use of improved surgical procedures and immunosuppression drugs have increased the 
success rate of vascularised intact pancreas transplantation. Between 1988 and 2016, there 
were 29,962 cases of successful vascularised pancreas transplantation worldwide (United 
Network for Organ Sharing, 2016). However, the use of islet transplantation to achieve insulin 
independence and alleviate complications of type 1 diabetes is suggested to be superior to whole 
pancreas transplantation or insulin therapy. Islet transplantation causes fewer complications 
and side effects than insulin therapy and it is easier to perform compared to whole pancreas 
transplantation. Insulin therapy is effective only if the patient fully subscribes to the 
consumption protocol and dosage and follow-up regimen and is supervised by a professional 
healthcare team. It should be noted that the aim of pancreas or islet transplantation is to achieve 
insulin independence, increase quality of life and diminish secondary diabetes complications 
(Robertson et al., 2010). At the early stages of islet transplantation experiments using induced 
diabetic rodents as models, the islets were shown to reverse diabetes. Transplantation of 
islet allografts at various sites on the body of diabetic rodents temporarily improved insulin 
requirement, but did not reverse diabetes for a period long enough to achieve complete insulin 
independence (Ballinger & Lacy, 1972; Najarian et al., 1977).  
Islet Xenotransplantation in Diabetes
Currently, islet allotransplantation procedures are limited by lack of donor sources 
(Collaborative Islet Transplant Registry, 2009; Shapiro, 2011; Thompson et al., 2011; Hani 
et al., 2010; Hani et al., 2014). For that reason, over the last decade, fewer than 1000 islet 
transplantation procedures have been performed worldwide (Collaborative Islet Transplant 
Registry, 2009). To overcome the shortage, alternative sources of islets have been proposed 
including pigs, non-human primates, cattle, sheep, goats and fish (Hani et al., 2010; Hani et al., 
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Figure 1. Cell therapy procedure in diabetes type 1. Pancreata are collected from donors (human or 
animal), then islets or stem cells are harvested from pancreas. After islet purification and stem cell 
growth in culture, viable islets or cells are transplanted into the recipients’ body.  
	
Figure 1. Cell therapy procedure in type 1 diabetes. Pancreata are collected from donors (human or animal), 
then islets or stem cells ar  harvested from pancreas. After isl t purifica ion and stem c ll growth in culture, 
viable islets or cells are transplanted into the recipients’ body
Homayoun Hani, Mohd-Azmi Mohd-Lila, Rasedee Abdullah, Zeenathul Nazariah Allaudin, Kazhal Sarsaifi and
Faez Firdaus Jesse Abdullah
76 Pertanika J. Sci. & Technol. 26 (1): 71 - 84 (2018)
2014; Vakhshiteh et al., 2013; Hani e al., 2015; Hani et al., 2016; Hani et al., 2017; Kean et al., 
2006). Although the best source of islets for human transplantation are non-human primates, 
due to issues like genetic homogeny, and ethics, safety and logistics, other sources have been 
investigated. Pig islets are one  potential source for xenotransplantation for humans because 
of compatibility based on similarity to insulin molecules and glucose kinetics between these 
species (van der Windt et al., 2012). However, among Muslims, tissues from porcine sources 
are not generally acceptable for human transplantation.
As with all tissue transplantations, outbred diversity, heterologous immunity and MHC 
expressions are barriers to long-term xenograft survival; thus, islet transplantation needs to 
address these issues of immune response and rejection, for instance, through immunosuppression 
and encapsulation (Thompson et al., 2011).
Safety Issues in Islet Therapy for Diabetes Mellitus
Stem cell therapy. Stem cells such as mesenchymal, embryonic and hematopoietic stem cells, 
have the potential for differentiation into insulin-secreting or islet-like cluster cells. Some 
pancreatic islet cells or islet progenitor cells can differentiate into new insulin-secreting cells 
to replace injured and old β-cells that are undergoing apoptosis (Figure 1) (Kirk et al., 2014). 
In cell therapy for type 1 diabetes, adult stem cells are probably more suitable than embryonic 
stem cells. Adult pluripotential stem cells are teratogenic and their use give rise to fewer 
ethical issues. Adult pluripotential stem cells readily differentiate into the tissue cells of their 
origin and would be of greater application in cell replacement therapy for diabetes. However, 
diabetes treatment methods using these stem cells are still not fully developed for use without 
dire adverse consequences (Habener, 2004).
Safety of islet transplantation. Islets are fraught with the tendency to undergo apoptosis, 
diminished functionality and viability during purification (Lipsett et al., 2006). The isolation 
and purification of islets from the pancreas are governed by the presence of growth factors, 
supportive matrix and physical and chemical stresses, such as osmotic, hypoxia and mechanical 
stresses, that determine the survival of the cells. Thus, optimisation of the islet isolation 
procedure is imperative for obtaining viable cells for transplantation. 
The success of islet transplantation is also determined by the site on the body, glucose and 
lipid concentrations (Lipsett et al., 2006) and the immunosuppressive drugs used. Graft sites 
that are naturally well-nourished and with an environment conducive for transplantation will 
increase the success of the treatment. In a recent study, the islets were first encapsulated with 
an immunprotector to avoid destruction by the immune system while retaining their ability to 
communicate with the environment (Lipsett et al., 2006).    
Although anti-rejection regimens for both islet and pancreas transplantation recipients are 
the same, however, complications arising from pancreas transplantation are higher than from 
islet transplantation (Moassesfar et al., 2016). Whole pancreas transplantation is most common 
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for patients with pancreatitis and pancreas dysfunction or failure, while islet cell transplantation 
is usually recommended for those patients with islet mass loss or destruction, mostly in type 
1 diabetes. Therefore, in type 1 diabetes, it is not necessary to transplant the whole pancreas 
even if it is less costly compared to islet transplantation. As the pancreas is a multifunction 
organ, if the graft is rejected by the immune system of recipients, then the whole organ, rather 
than just the islet cells, must be replaced.    
Islet xenotransplantation. Safety protocols for islet transplantation are also applicable for islet 
allotransplantation and xenotransplantation. Among issues associated with transplantation is the 
transmission of infections. To ensure success of transplantation, precautions have to be taken 
to avoid transmission of infectious agents from the donor and the environment to the recipient 
(U.S. Food and Drug Administration, 2003; Mueller et al., 2011). One threat of infection 
concerns the use of porcine islet cells. Porcine endogenous retrovirus infection in islets is often 
a threat in xenotransplantation. Other infectious agents such as the cytomegalo virus, herpes 
virus and lymphotropic herpes virus as well as bacteria that are resident in porcine islets can 
pose a threat to recipients. Thus, to avoid infections, the animals serving as sources of islets 
must first be screened to ensure they are free from zoonotic organisms. However, it is often 
difficult to avoid contamination by infectious agents because the porcine retrovirus genome, 
for instance, is integrated in the animal genome and can go undetected and in this way, be 
transmitted to recipients during transplantation (van der Windt et al., 2012; Zhu et al., 2014). 
Economics
To ensure the safety of recipients, animals like pigs that are the source of islets must be bred in 
expensive sterile and clean facilities. It is estimated that a facility complete with the equipment 
for cleaning breeding of 100 animals can cost more than USD10 million with a maintenance 
cost of between USD1 to 2 million per year. However, these breeding facilities are necessary 
to ensure supply of islets that are clean and safe for human use (van der Windt et al., 2012). 
Based on reports, the cost of insulin therapy over the long term is higher than islet cell 
transplantation (Berwick, 2016). In 2016, the cost of insulin therapy was estimated at $71,000 
per quality-adjusted life year (QALY) (Berwick, 2016), while for islet transplantation it was 
estimated at $50,000/QALY. The initial cost of islet transplantation is higher than that of 
insulin therapy, but over the years, due to continuous and long-term application, the total cost 
of insulin therapy eventually becomes much higher than that of islet transplantation (Beckwith 
et al., 2012). 
Pancreas transplantation is marginally cheaper at a total cost of USD135,000 than islet 
cell transplantation at USD139,000. These expenses were calculated based on the cost of 
transplantation procedures and hospitalisation after surgery (Table 2).
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Table 2 
Comparison between treatments for type 1 diabetes 
Therapy Type Global practice rate Cost Advantages Disadvantages
Insulin Injection Recombinant
Animal
23.9 million (2000) 
60,000 injections 
throughout life-
timea
$663,000/20years
$71,000 QALYsb
Easy access 
and personally 
practicable; 
Temporarily capable 
of controlling blood 
glucose levelc
Hypoglycemia, unusual 
ocular disturbance, 
dermatologic reaction 
(lipohyperthrophy), 
hypersensitivity, 
immunologic response 
(anaphylaxis), 
hypertension, weight gain, 
myocardial infarction, renal 
dysfunction, hemolytic 
anemia and gastrointestinal 
distressc
Pancreas 
Transplantation
Intact
Partial
2328/yeard $ ~134,750e
(Mean total cost 
incorporating
complications)
One proper donor 
may be sufficiente
Proper donor shortage;
Need surgery;
High rejection riske
Islet Transplantation Auto
Allo
<100/yearf $659,000/20year
$61,000 QALYs
$ ~139,000 
(Mean total cost 
incorporating
second islet
transplants (ITA)b
No surgery 
procedures 
necessary; Less 
post-transplantation 
complication 
compared 
to pancreas 
transplantation;
Consistent islet 
yielde
Lack of donors; More 
than one donor may be 
needed to achieve insulin 
independency; 
Need isolation processing;
Transplanted β-islet cells 
may be rejected within 
several years and must be 
repeated every couple of 
years at a cost of $120,000 
per transplantb,e
Islet 
Xenotransplantation
Fatal Not  routinely 
practised 
$60,700 QALYsb No isolation 
procedure 
necessary; 
Proliferation and 
maturation in vivo
Not fully functional 
until >4 months after 
transplantation;
Nonsurvival C-section 
in sow; Need for many 
foetuses
Neonatal No need for harmful 
purification process;
Proliferation in vitro 
and in vivo after 
transplantation;
Resistance against 
hypoxia; Preferable 
breeding logistics
Not fully functional until 
>4 weeks
Young More preferable 
breeding logistics 
vs. adult >2 years
Fragility of islets; Difficult 
to obtain consistent yields;
Less preferable breeding 
logistics vs. neonatal57
Adult Consistent islet 
yields
Non-preferable breeding 
logistics; High costg
Stem cells Polypotent
Multipotent
N/A N/A Can be harvested 
from adult tissues 
(Habener, 2004); 
Unlimited sources 
of β-cellh
Teratogenic behaviour; 
Auto-immune attack by 
recipient body against 
autograft stem cellsh
a) Al-Tabakha et al. (2008); b) Beckwith et al. (2012); c) Insulin side effects (2017); d) Estimated number of organ transplantations worldwide 
in 2014 (2014); e) Moassesfar et al. (2016); f) Islet Transplantation Technology (2010); g) van der Windt et al. (2012); h) Habener (2004).
Type 1 Diabetes Treatments
79Pertanika J. Sci. & Technol. 26 (1): 71 - 84 (2018)
CONCLUSION
Cell therapy, whether with islets or stem cells, is a promising treatment for type 1 diabetes 
that could provide long-lasting insulin independence. However, these methods of therapy for 
diabetics are limited by cell quality, donor availability and financial constraints. In the final 
analysis, the choice of therapeutic means is governed by reliability of the technique to provide 
a long-lasting cure for diabetes. Currently, cell therapy is only affordable by the affluent and 
is not within the means of low-income patients. Given more time and with greater advances 
in technology, cell therapy for diabetics may be affordable for all.
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